Image pharmaphorum Editor Digital How can pharma teams optimise their HCP portals to strengthe... In recent years, pharma companies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time bet R&D How Design of Experiments enriches life sciences’ findings Design of Experiments (DOE) is a methodology misunderstood by many, understood by some, and actively used by even fewer than that. Oncology Sponsored How can digital and AI optimise the delivery of patient supp... How can digital and AI optimise the delivery of patient support programs in cancer? Digital 2023 predictions and challenges in the healthcare business With a new year comes an opportunity for professionals in the healthcare industry to evaluate goals and initiatives for 2023. Load more results
Digital How can pharma teams optimise their HCP portals to strengthe... In recent years, pharma companies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time bet
R&D How Design of Experiments enriches life sciences’ findings Design of Experiments (DOE) is a methodology misunderstood by many, understood by some, and actively used by even fewer than that.
Oncology Sponsored How can digital and AI optimise the delivery of patient supp... How can digital and AI optimise the delivery of patient support programs in cancer?
Digital 2023 predictions and challenges in the healthcare business With a new year comes an opportunity for professionals in the healthcare industry to evaluate goals and initiatives for 2023.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
